Guardant Health, Inc. (GH): who owns it and who trades it
As of Nov 16, 2026, GH insiders reported 138 open-market sales worth $168M and 1 purchase worth $78.5K in the last 12 months, with 48% of the sale value made under pre-set 10b5-1 plans. The largest seller was AmirAli Talasaz (CEO), with $79M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Guardant Health
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and Congress mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GH
592 funds and institutions reported GH shares worth $20.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 5.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 7.62M | 5.75% | $1.1B | -34% |
| T. Rowe Price Associates | 6.51M | 4.91% | $977M | -7% |
| Vanguard Capital Management LLC | 5.76M | 4.34% | $864M | +2% |
| FMR LLC (Fidelity) | 5.49M | 4.14% | $823M | +33% |
| Vanguard Portfolio Management LLC | 5.45M | 4.11% | $817M | -7% |
| Invesco Ltd. | 4.43M | 3.34% | $665M | -10% |
| Goldman Sachs Group Inc | 3.78M | 2.85% | $566M | -15% |
| Two Sigma Investments, LP | 3.72M | 2.80% | $558M | -12% |
| Capital International Investors | 3.40M | 2.56% | $510M | -2% |
| Deep Track Capital, LP | 3.39M | 2.56% | $509M | +2% |
| Franklin Resources Inc | 3.24M | 2.44% | $486M | -6% |
| Ameriprise Financial Inc | 3.15M | 2.38% | $473M | +123% |
| Fuller & Thaler Asset Management, Inc. | 2.63M | 1.98% | $394M | +3% |
| Geode Capital Management, LLC | 2.52M | 1.90% | $378M | -28% |
| Baillie Gifford & Co | 2.28M | 1.72% | $343M | -41% |
| State Street Corp | 2.26M | 1.71% | $340M | -22% |
| Federated Hermes, Inc. | 2.00M | 1.51% | $300M | +6% |
| Eventide Asset Management, LLC | 1.96M | 1.48% | $294M | -17% |
| Lord, Abbett & Co. LLC | 1.81M | 1.37% | $272M | -5% |
| Jane Street Group, LLC | 1.78M | 1.34% | $268M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GH insiders reported $78.5K of open-market purchases and $168M of sales. 48% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Musa Tariq | Director | Sale plan | 116 | $165.88 | $19.2K | Form 4 |
| Oct 14, 2026 | Alex M Azar II | Director | Sale plan | 69 | $159.89 | $11K | Form 4 |
| Sep 16, 2026 | Steve E. Krognes | Director | Sale | 1,103 | $174.46 | $192K | Form 4 |
| Sep 16, 2026 | Steve E. Krognes | Director | Sale | 971 | $177.48 | $172K | Form 4 |
| Sep 16, 2026 | Steve E. Krognes | Director | Sale | 1,300 | $176.34 | $229K | Form 4 |
| Sep 16, 2026 | Steve E. Krognes | Director | Sale | 3,300 | $175.42 | $579K | Form 4 |
| Sep 16, 2026 | Alex M Azar II | Director | Sale plan | 826 | $175.00 | $145K | Form 4 |
| Sep 16, 2026 | Musa Tariq | Director | Sale plan | 116 | $175.00 | $20.3K | Form 4 |
| Sep 15, 2026 | Darya Chudova | Chief Technology Officer | Sale | 7,738 | $178.00 | $1.4M | Form 4 |
| Sep 11, 2026 | Kumud Kalia | Chief Information Office | Sale | 4,000 | $158.05 | $632K | Form 4 |
| Aug 21, 2026 | AmirAli Talasaz | CEO | Sale | 20,888 | $169.16 | $3.5M | Form 4 |
| Aug 21, 2026 | AmirAli Talasaz | CEO | Sale | 9,023 | $168.20 | $1.5M | Form 4 |
| Aug 21, 2026 | AmirAli Talasaz | CEO | Sale | 7,589 | $170.29 | $1.3M | Form 4 |
| Aug 17, 2026 | Musa Tariq | Director | Sale plan | 116 | $156.45 | $18.1K | Form 4 |
| Aug 12, 2026 | Terilyn J. Monroe | Chief People Officer | Sale | 400 | $167.92 | $67.2K | Form 4 |
| Aug 12, 2026 | Terilyn J. Monroe | Chief People Officer | Sale | 13,248 | $166.11 | $2.2M | Form 4 |
| Aug 12, 2026 | Terilyn J. Monroe | Chief People Officer | Sale | 19,014 | $165.16 | $3.1M | Form 4 |
| Aug 12, 2026 | Terilyn J. Monroe | Chief People Officer | Sale | 9,934 | $164.27 | $1.6M | Form 4 |
| Aug 12, 2026 | Terilyn J. Monroe | Chief People Officer | Sale | 3,704 | $163.41 | $605K | Form 4 |
| Aug 10, 2026 | Chris Freeman | Chief Commercial Officer | Sale | 35,364 | $169.63 | $6M | Form 4 |
| Aug 10, 2026 | Chris Freeman | Chief Commercial Officer | Sale | 7,365 | $168.79 | $1.2M | Form 4 |
| Aug 10, 2026 | Chris Freeman | Chief Commercial Officer | Sale | 3,463 | $167.38 | $580K | Form 4 |
| Aug 10, 2026 | Chris Freeman | Chief Commercial Officer | Sale | 17,413 | $170.24 | $3M | Form 4 |
| Aug 5, 2026 | Medina Manuel Hidalgo | Director | Sale | 950 | $163.95 | $156K | Form 4 |
| Aug 5, 2026 | Medina Manuel Hidalgo | Director | Sale | 750 | $164.61 | $123K | Form 4 |
| Aug 4, 2026 | Ian T Clark | Director | Sale | 9,088 | $158.98 | $1.4M | Form 4 |
| Aug 4, 2026 | Ian T Clark | Director | Sale | 5,092 | $158.80 | $809K | Form 4 |
| Jul 16, 2026 | Musa Tariq | Director | Sale plan | 116 | $163.29 | $18.9K | Form 4 |
| Jun 29, 2026 | AmirAli Talasaz | CEO | Sale plan | 46,663 | $152.20 | $7.1M | Form 4 |
| Jun 29, 2026 | AmirAli Talasaz | CEO | Sale plan | 40 | $153.00 | $6.1K | Form 4 |
| Jun 29, 2026 | AmirAli Talasaz | CEO | Sale plan | 25,812 | $150.53 | $3.9M | Form 4 |
| Jun 29, 2026 | AmirAli Talasaz | CEO | Sale plan | 70,513 | $151.47 | $10.7M | Form 4 |
| Jun 26, 2026 | AmirAli Talasaz | CEO | Sale plan | 52,935 | $151.16 | $8M | Form 4 |
| Jun 26, 2026 | AmirAli Talasaz | CEO | Sale plan | 64,037 | $150.49 | $9.6M | Form 4 |
| Jun 22, 2026 | Musa Tariq | Director | Sale plan | 1,951 | $131.16 | $256K | Form 4 |
| Jun 22, 2026 | Myrtle S Potter | Director | Sale plan | 1,556 | $131.16 | $204K | Form 4 |
| Jun 16, 2026 | Musa Tariq | Director | Sale plan | 116 | $130.19 | $15.1K | Form 4 |
| Jun 15, 2026 | Kumud Kalia | Chief Information Office | Sale | 600 | $131.08 | $78.6K | Form 4 |
| Jun 15, 2026 | Kumud Kalia | Chief Information Office | Purchase | 600 | $130.76 | $78.5K | Form 4 |
| Jun 11, 2026 | Kumud Kalia | Chief Information Office | Sale | 3,418 | $130.24 | $445K | Form 4 |
| Jun 10, 2026 | Kumud Kalia | Chief Information Office | Sale | 600 | $130.86 | $78.5K | Form 4 |
| Jun 10, 2026 | Kumud Kalia | Chief Information Office | Sale | 5,000 | $130.41 | $652K | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 554 | $130.21 | $72.1K | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 900 | $131.78 | $119K | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 100 | $132.55 | $13.3K | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 13,787 | $128.25 | $1.8M | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 49,716 | $125.57 | $6.2M | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 1,100 | $127.02 | $140K | Form 4 |
| Jun 5, 2026 | Helmy Eltoukhy | CEO | Sale | 33,843 | $126.33 | $4.3M | Form 4 |
| Jun 5, 2026 | Michael Brian Bell | CFO | Sale | 2,000 | $128.62 | $257K | Form 4 |
| Jun 4, 2026 | Steve E. Krognes | Director | Sale | 9,294 | $132.51 | $1.2M | Form 4 |
| Jun 3, 2026 | Meghan V. Joyce | Director | Sale plan | 3,516 | $126.52 | $445K | Form 4 |
| Jun 3, 2026 | Meghan V. Joyce | Director | Sale plan | 650 | $128.02 | $83.2K | Form 4 |
| Jun 3, 2026 | Meghan V. Joyce | Director | Sale plan | 106 | $129.31 | $13.7K | Form 4 |
| Jun 3, 2026 | Meghan V. Joyce | Director | Sale plan | 5,728 | $127.11 | $728K | Form 4 |
| May 28, 2026 | Medina Manuel Hidalgo | Director | Sale | 1,000 | $130.06 | $130K | Form 4 |
| May 27, 2026 | John G. Saia | Chief Legal Officer | Sale plan | 9,994 | $125.08 | $1.3M | Form 4 |
| May 27, 2026 | John G. Saia | Chief Legal Officer | Sale plan | 6 | $126.08 | $756 | Form 4 |
| May 22, 2026 | Chris Freeman | Chief Commercial Officer | Sale | 24,406 | $118.67 | $2.9M | Form 4 |
| May 20, 2026 | John G. Saia | Chief Legal Officer | Sale plan | 7,181 | $107.23 | $770K | Form 4 |
| May 20, 2026 | John G. Saia | Chief Legal Officer | Sale plan | 5,632 | $105.34 | $593K | Form 4 |
| May 20, 2026 | John G. Saia | Chief Legal Officer | Sale plan | 7,187 | $106.71 | $767K | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 200 | $100.95 | $20.2K | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 37,163 | $111.14 | $4.1M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 900 | $102.57 | $92.3K | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 9,852 | $108.97 | $1.1M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 26,352 | $112.76 | $3M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 37,900 | $112.02 | $4.2M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 28,908 | $110.10 | $3.2M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 1,366 | $103.82 | $142K | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 11,919 | $105.01 | $1.3M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 1,200 | $105.88 | $127K | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 21,171 | $106.99 | $2.3M | Form 4 |
| May 20, 2026 | AmirAli Talasaz | CEO | Sale plan | 33,069 | $108.11 | $3.6M | Form 4 |
| May 20, 2026 | Ian T Clark | Director | Sale | 6,876 | $106.90 | $735K | Form 4 |
| May 20, 2026 | Medina Manuel Hidalgo | Director | Sale | 250 | $107.07 | $26.8K | Form 4 |
| May 20, 2026 | Medina Manuel Hidalgo | Director | Sale | 1,000 | $107.10 | $107K | Form 4 |
| May 18, 2026 | Musa Tariq | Director | Sale plan | 116 | $95.96 | $11.1K | Form 4 |
| May 12, 2026 | AmirAli Talasaz | CEO | Sale plan | 50,000 | $100.32 | $5M | Form 4 |
| Apr 16, 2026 | Musa Tariq | Director | Sale plan | 116 | $84.83 | $9.8K | Form 4 |
| Apr 6, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 3,832 | $92.68 | $355K | Form 4 |
| Mar 18, 2026 | Musa Tariq | Director | Sale plan | 348 | $88.09 | $30.7K | Form 4 |
| Mar 16, 2026 | Michael Brian Bell | CFO | Sale | 3,000 | $87.04 | $261K | Form 4 |
| Mar 6, 2026 | Medina Manuel Hidalgo | Director | Sale | 300 | $91.30 | $27.4K | Form 4 |
| Mar 6, 2026 | Medina Manuel Hidalgo | Director | Sale | 1,000 | $91.61 | $91.6K | Form 4 |
| Mar 4, 2026 | Kumud Kalia | Chief Information Office | Sale | 13,020 | $95.73 | $1.2M | Form 4 |
| Mar 4, 2026 | Kumud Kalia | Chief Information Office | Sale | 26,980 | $95.12 | $2.6M | Form 4 |
| Jan 21, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 1,703 | $112.34 | $191K | Form 4 |
| Jan 21, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 3,249 | $115.70 | $376K | Form 4 |
| Jan 21, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 3,619 | $113.48 | $411K | Form 4 |
| Jan 7, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 88 | $113.44 | $10K | Form 4 |
| Jan 7, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 3,632 | $112.62 | $409K | Form 4 |
| Jan 7, 2026 | Terilyn J. Monroe | Chief People Officer | Sale plan | 6,311 | $111.75 | $705K | Form 4 |
| Dec 17, 2025 | Musa Tariq | Director | Sale plan | 116 | $101.46 | $11.8K | Form 4 |
| Dec 15, 2025 | Helmy Eltoukhy | CEO | Sale | 83,945 | $103.80 | $8.7M | Form 4 |
| Dec 15, 2025 | Helmy Eltoukhy | CEO | Sale | 6,620 | $104.02 | $689K | Form 4 |
| Dec 15, 2025 | Darya Chudova | Chief Technology Officer | Sale | 5,451 | $104.04 | $567K | Form 4 |
| Dec 8, 2025 | AmirAli Talasaz | CEO | Sale | 30,760 | $105.34 | $3.2M | Form 4 |
| Dec 8, 2025 | AmirAli Talasaz | CEO | Sale | 4,240 | $106.00 | $449K | Form 4 |
| Dec 8, 2025 | AmirAli Talasaz | CEO | Sale | 15,000 | $104.21 | $1.6M | Form 4 |
Latest 100 of 139 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| AmirAli Talasaz | Co-Chief Executive Officer, Director | – | $79M | Aug 21, 2026 |
| Helmy Eltoukhy | Co-Chief Executive Officer, Director | – | $22M | Jun 5, 2026 |
| Chris Freeman | Chief Commercial Officer | – | $16.9M | Aug 10, 2026 |
| Terilyn J. Monroe | Chief People Officer | – | $15.9M | Aug 12, 2026 |
| Michael Brian Bell | Chief Financial Officer | – | $8.8M | Jun 5, 2026 |
| Ian T Clark | Director | – | $6.1M | Aug 4, 2026 |
| Kumud Kalia | Chief Information Officer | $78.5K | $5.9M | Sep 11, 2026 |
| Darya Chudova | Chief Technology Officer | – | $4.4M | Sep 15, 2026 |
| John G. Saia | Chief Legal Officer | – | $3.4M | May 27, 2026 |
| Steve E. Krognes | Director | – | $2.4M | Sep 16, 2026 |
| Meghan V. Joyce | Director | – | $1.3M | Jun 3, 2026 |
| Medina Manuel Hidalgo | Director | – | $793K | Aug 5, 2026 |
| Musa Tariq | Director | – | $422K | Oct 16, 2026 |
| Myrtle S Potter | Director | – | $204K | Jun 22, 2026 |
| Alex M Azar II | Director | – | $156K | Oct 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GH short interest
Moderate short interest. 7.0% of GH shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 27%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.43M GH shares were sold short, 7.0% of the shares outstanding, down 19.2% from the report before. At the average daily volume of 1.75M shares, buying them all back would take about 5.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.43M | 6.97% | -19% | 1.75M | 5.4 |
| Oct 15, 2026 | 11.67M | 8.70% | -2% | 1.75M | 6.7 |
| Sep 30, 2026 | 11.92M | 8.88% | +8% | 1.92M | 6.2 |
| Sep 15, 2026 | 11.02M | 8.21% | -0% | 1.67M | 6.6 |
| Aug 31, 2026 | 11.05M | 8.23% | -1% | 2.10M | 5.2 |
| Aug 14, 2026 | 11.19M | 8.34% | -2% | 1.95M | 5.7 |
| Jul 31, 2026 | 11.42M | 8.51% | No change | 2.12M | 5.4 |
| Jul 15, 2026 | 11.42M | 8.61% | -6% | 2.82M | 4.0 |
| Jun 30, 2026 | 12.14M | 9.16% | -7% | 4.25M | 2.9 |
| Jun 15, 2026 | 13.09M | 9.87% | -1% | 2.05M | 6.4 |
| May 29, 2026 | 13.21M | 9.96% | +2% | 2.93M | 4.5 |
| May 15, 2026 | 12.93M | 9.75% | +1% | 1.83M | 7.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded GH
Since Nov 17, 2024, 2 members of Congress reported 2 purchases and 0 sales of GH. The latest was a purchase by Jonathan L. Jackson on Sep 28, 2026, reported Oct 19, 2026.
Purchases 2Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Jonathan L. Jackson (D-IL) | Purchase | $15K–$50K | Joint | Oct 19, 2026 | Report |
| Nov 21, 2025 | Sheldon Whitehouse (D-RI) | Purchase | $1K–$15K | Self | Dec 1, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Guardant Health company events
Guardant Health filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Nov 3, 2026LeadershipThe Board of Directors of Guardant Health, Inc. increased the number of directors on the Board to 11 and appointed Kevin R. Sayer, 68, as a Class II director of the Company, to be effective as of November 2, 2026. Filing
- Nov 3, 2026LeadershipThe independent members of the Board of Directors of Guardant Health, Inc. approved the grant of performance-based restricted stock units under the Company’s 2018 Incentive Award Plan to each of the Company’s founders and Co-Chief Executive Officers, Helmy Eltoukhy and AmirAli Talasaz. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 27, 2026LeadershipGuardant Health, Inc. announced the resignation of Craig Eagle, M.D., the Company’s Chief Medical Officer, to be effective as of May 8, 2026. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Guardant Health financials
Famous investors that hold GH
6 of the 50 well-known investors we track reported holding GH in their latest 13F filing. The largest position is Ken Griffin's, worth $462M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.59M | $462M | 0.3% | +79% |
| Israel Englander · Millennium Management | Q3 2026 | 1.12M | $199M | 0.2% | -31% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 637,905 | $114M | 0.2% | -31% |
| Cathie Wood · ARK Investment Management | Q3 2026 | 607,173 | $108M | 0.6% | +20% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 109,440 | $19.5M | 0.1% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 4,159 | $742K | 0.0% | -2% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named GH in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G | 5.8% |
| Nov 5, 2026 | FMR LLC | 13G | 5.8% |
Questions about Guardant Health, Inc. (GH) stock
Who owns the most GH stock?
The largest reported owner of Guardant Health, Inc. (GH) is BlackRock, Inc., with 5.7% of the company. In total, 592 funds and institutions reported holding GH at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are GH insiders buying or selling?
In the last 12 months, GH insiders reported 1 open-market purchase worth $78.5K and 138 sales worth $168M. The latest trade was on Oct 16, 2026. See every trade.
What is the short interest in GH?
As of Oct 30, 2026, 9.43M GH shares were sold short, 7.0% of the shares outstanding, down 19.2% from the report before. At the average daily volume of 1.75M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.
Have members of Congress traded GH?
Yes. 2 members of Congress reported 2 purchases and 0 sales of GH since Nov 17, 2024. The latest was reported on Oct 19, 2026. See the trades.
Which famous investors hold GH?
6 of the 50 well-known investors we track reported GH in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $462M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.